Methods and apparatus for parallel scheduling of frequency resources for communication nodes
    11.
    发明授权
    Methods and apparatus for parallel scheduling of frequency resources for communication nodes 有权
    用于通信节点频率资源并行调度的方法和装置

    公开(公告)号:US08483735B2

    公开(公告)日:2013-07-09

    申请号:US12869317

    申请日:2010-08-26

    IPC分类号: H04B7/00

    摘要: Various schedulers are disclosed for use within a network node of a radio access network. A scheduler can be configured to divide a defined frequency bandwidth into a plurality of bandwidth pipes. The scheduler then develops sets of nodes that are candidates for using corresponding ones of the bandwidth pipes to communicate with the network node during a communication time interval. At least one of the sets contains a plurality of candidate nodes. The scheduler operates separate parallel processes that are arranged for computing metrics for the sets of nodes. The scheduler assigns one of the nodes in each set of nodes to the corresponding bandwidth pipe in response to the computed metrics. The scheduler may divide the defined frequency bandwidth into a plurality of non-overlapping bandwidth pipes so that metrics for candidate nodes in one of the sets can be computed independently from candidate nodes in another one of the sets.

    摘要翻译: 公开了在无线电接入网络的网络节点内使用的各种调度器。 调度器可以被配置为将定义的频率带宽划分成多个带宽管道。 然后,调度器开发出在通信时间间隔期间使用对应的带宽管道与网络节点进行通信的候选者的节点集合。 至少一个集合包含多个候选节点。 调度器操作单独的并行进程,其被布置用于计算节点集合的度量。 调度器响应于所计算的度量,将每组节点中的节点之一分配给相应的带宽管道。 调度器可以将定义的频率带宽划分为多个不重叠的带宽管道,使得可以独立于另一组中的候选节点来计算其中一个集合中的候选节点的度量。

    TOOL MAGAZINE
    12.
    发明申请
    TOOL MAGAZINE 有权
    工具杂志

    公开(公告)号:US20120241342A1

    公开(公告)日:2012-09-27

    申请号:US13071493

    申请日:2011-03-24

    申请人: Ying Sun

    发明人: Ying Sun

    IPC分类号: B65G1/12

    摘要: A machine tool is provided with a tool magazine including a guiding plate, a turntable and holders. The guiding plate includes an annular groove with a semi-circular section and a semi-oval section. The semi-circular section is defined by a radius. The semi-oval section is defined by a semi-major axis identical to the radius of the semi-circular section and a semi-minor axis shorter than the semi-major axis. The turntable includes claws extending from the periphery. Each of the holders is pivotally connected to a related one of the claws and includes an end for holding a tool and another end formed with a ball movably located in the annular groove. Thus, some of the holders of which the balls are located in the semi-circular section of the annular groove close while the other holders of which the balls are located in the semi-oval section of the annular groove open.

    摘要翻译: 一种机床设置有包括引导板,转台和保持器的工具仓。 引导板包括具有半圆形截面和半椭圆形截面的环形槽。 半圆形部分由半径定义。 半椭圆形部分由与半圆形部分的半径相同的半长轴和短于半长轴的半短轴限定。 转盘包括从周边延伸的爪。 每个保持器枢转地连接到相关的一个爪中,并且包括用于保持工具的端部和形成有可移动地位于环形槽中的球的另一端。 因此,其中球位于环形槽的半圆形部分中的一些保持器关闭,而球位于环形槽的半椭圆形部分中的其他保持器打开。

    Device for treatment of barrier membranes
    13.
    发明授权
    Device for treatment of barrier membranes 有权
    阻隔膜处理装置

    公开(公告)号:US08239017B2

    公开(公告)日:2012-08-07

    申请号:US12272198

    申请日:2008-11-17

    IPC分类号: A61N1/30

    摘要: The present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a carrier; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode and the second conductive electrode are in ionic communication with the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface.

    摘要翻译: 本发明的特征在于具有阻挡膜接触表面的装置,该装置包括:电源; 第一导电电极; 第二导电电极; 和承运人; 其中所述电源与所述第一导电电极和所述第二导电电极电连通,其中所述第一导电电极和所述第二导电电极与所述载体离子连通,并且其中所述载体与所述阻挡膜接触表面连通 。

    Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    14.
    发明授权
    Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors 有权
    喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂

    公开(公告)号:US08236807B2

    公开(公告)日:2012-08-07

    申请号:US12505725

    申请日:2009-07-20

    摘要: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译: 本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐,酯或前药。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Method and a device in a wireless communication system
    15.
    发明授权
    Method and a device in a wireless communication system 有权
    无线通信系统中的方法和设备

    公开(公告)号:US08170575B2

    公开(公告)日:2012-05-01

    申请号:US13058661

    申请日:2008-08-12

    IPC分类号: H04W72/08

    CPC分类号: H04L1/0027 H04L1/0025

    摘要: In a wireless communication system, a base station adaptively schedule CQI reports form mobile stations. By adaptively prioritizing the CQI report from the mobile station against the uplink traffic and control data, the CQI reporting rate avoids unnecessary overhead in the uplink while maintaining good performance. The CQI reports are requested in response to a calculated weighting factor which is based on channel coherence time that can be estimated by the base station. The adaptivity in the CQI reporting allows achieving an optimal tradeoff between uplink traffic data and downlink control feedback signaling.

    摘要翻译: 在无线通信系统中,基站从移动台自适应地调度CQI报告。 通过对来自移动台的CQI报告对上行流量和控制数据进行自适应优先排序,CQI报告速率避免了上行链路中不必要的开销,同时保持了良好的性能。 响应于基于可由基站估计的信道相干时间的计算的加权因子来请求CQI报告。 CQI报告中的适应性允许在上行链路业务数据和下行链路控制反馈信令之间实现最佳权衡。

    System and method for generating MR myocardial perfusion maps without user interaction
    16.
    发明授权
    System and method for generating MR myocardial perfusion maps without user interaction 有权
    用于产生MR心肌灌注图的系统和方法,无需用户交互

    公开(公告)号:US08139838B2

    公开(公告)日:2012-03-20

    申请号:US12431888

    申请日:2009-04-29

    IPC分类号: G06K9/00

    摘要: A method for automatically generating a myocardial perfusion map from a sequence of magnetic resonance (MR) images includes determining a region of interest (ROI) in a reference frame selected from a time series of myocardial perfusion MR image slices, registering each image slice in the time series of slices to the reference frame to obtain a series of registered ROIs, and using the series of registered ROIs to segment endo- and epi-cardial boundaries of a myocardium in the ROI.

    摘要翻译: 从磁共振(MR)图像序列自动生成心肌灌注图的方法包括确定选自心肌灌注MR图像切片的时间序列的参考帧中的感兴趣区域(ROI),将每个图像切片记录在 时间序列切片到参考帧以获得一系列注册的ROI,并且使用一系列注册的ROI来分割ROI中的心肌的内部和外部的边界。

    Tri-peptide hepatitis C serine protease inhibitors
    20.
    发明授权
    Tri-peptide hepatitis C serine protease inhibitors 有权
    三肽丙型肝炎丝氨酸蛋白酶抑制剂

    公开(公告)号:US07718769B2

    公开(公告)日:2010-05-18

    申请号:US11602586

    申请日:2006-11-20

    IPC分类号: A61K38/00

    CPC分类号: C07K5/0808 A61K38/00

    摘要: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译: 本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐,酯或前药。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。